BACKGROUND: Measuring biomarkers (e.g., volatile organic compounds [VOCs]) in exhaled breath is an attractive approach to monitor airway inflammation in asthma and other lung diseases. E-Nose technology has been studied to identify VOCs in exhaled breath. OBJECTIVE: We compared e-Nose respiratory patterns in a pediatric cohort with asthma to classificate children with different asthma control. METHODS: This cross-sectional study involved 38 children: 28 with asthma and 10 healthy controls . The asthmatic patients were categorized as having controlled (AC), partially controlled (APC) or uncontrolled asthma (ANC). Clinical exams, exhaled breath collection for generating e-Nose VOC profiles, and spirometry were performed. Exhaled breath samples were obtained using a commercial electronic nose (Cyranose 320; Smith Detections, Pasadena, CA, USA). The discriminative ability of breathprints werinvestigated by principal component analysis and penalized logistic regression. RESULTS: The E-nose was able to discriminate between the CON (controls)+AC and the ANC+APC group with an area under the curve [AUC] of 0.85 (95% confidence interval [CI] 0.72 to 0.98) and a cross-validated AUC of 0.80 (95% CI 0.70 to 0.85). Sensitivity and specificity calculated using the Youden index were 0.79 and 0.84, respectively. CONCLUSION: Exhaled biomarker patterns were easy to obtain with the device and were able to differentiate children with uncontrolled symptomatic asthma from asymptomatic controls.
BACKGROUND: Measuring biomarkers (e.g., volatile organic compounds [VOCs]) in exhaled breath is an attractive approach to monitor airway inflammation in asthma and other lung diseases. E-Nose technology has been studied to identify VOCs in exhaled breath. OBJECTIVE: We compared e-Nose respiratory patterns in a pediatric cohort with asthma to classificate children with different asthma control. METHODS: This cross-sectional study involved 38 children: 28 with asthma and 10 healthy controls . The asthmatic patients were categorized as having controlled (AC), partially controlled (APC) or uncontrolled asthma (ANC). Clinical exams, exhaled breath collection for generating e-Nose VOC profiles, and spirometry were performed. Exhaled breath samples were obtained using a commercial electronic nose (Cyranose 320; Smith Detections, Pasadena, CA, USA). The discriminative ability of breathprints werinvestigated by principal component analysis and penalized logistic regression. RESULTS: The E-nose was able to discriminate between the CON (controls)+AC and the ANC+APC group with an area under the curve [AUC] of 0.85 (95% confidence interval [CI] 0.72 to 0.98) and a cross-validated AUC of 0.80 (95% CI 0.70 to 0.85). Sensitivity and specificity calculated using the Youden index were 0.79 and 0.84, respectively. CONCLUSION: Exhaled biomarker patterns were easy to obtain with the device and were able to differentiate children with uncontrolled symptomatic asthma from asymptomatic controls.
Authors: I G van der Sar; N Wijbenga; M E Hellemons; C C Moor; G Nakshbandi; J G J V Aerts; O C Manintveld; M S Wijsenbeek Journal: Respir Res Date: 2021-09-17